Erasca Partners with BMS to Advance ERAS-0015 in Pancreatic Cancer

Share on Social Media

PRMT5 inhibitor
Image: Pixels

Erasca partners with Bristol Myers Squibb to evaluate pan-RAS inhibitor ERAS-0015 with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer.

Written By: Umesh Hanumante, M.Pharm (RA)

Reviewed By: Pharmacally Editorial Team

Erasca has entered a clinical trial collaboration with Bristol Myers Squibb (BMS) to evaluate its pan-RAS molecular glue ERAS-0015 alongside investigational PRMT5 inhibitor navlimetostat (BMS-986504) in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). The Phase 1/2 development programme will investigate whether simultaneously targeting RAS signalling and PRMT5 can improve antitumour activity in this molecularly defined pancreatic cancer population.

Dual Targeting of RAS and PRMT5

Under the clinical trial collaboration and supply agreement (CTCSA), BMS will sponsor the clinical trial, while Erasca will provide ERAS-0015. Both companies will retain their respective development and commercial rights to their compounds. The agreement is mutually non-exclusive, allowing both parties to pursue additional development collaborations involving their respective assets.

The combination addresses a specific biological vulnerability in MTAP-deleted pancreatic cancer. Nearly all pancreatic cancers with MTAP deletion also harbour co-occurring RAS mutations, creating a potential opportunity to target two complementary molecular dependencies.

MTAP (methylthioadenosine phosphorylase) deletion is a recurrent genetic alteration in several cancers. Its loss alters cellular methylation pathways and creates increased dependence on protein arginine methyltransferase 5 (PRMT5), an enzyme involved in RNA processing, gene regulation and other essential cellular functions.

Navlimetostat, an investigational PRMT5 inhibitor developed by BMS, targets this pathway. Combining PRMT5 inhibition with RAS pathway suppression could potentially exploit the metabolic and signalling vulnerabilities associated with MTAP-deleted tumours.

ERAS-0015 Adds Pan-RAS Inhibition

ERAS-0015 is an investigational oral pan-RAS molecular glue that inhibits RAS signalling. Unlike mutant-selective RAS inhibitors, which target specific altered forms of the protein, ERAS-0015 also inhibits wild-type RAS variants.

This broader activity could be relevant in tumours where multiple RAS variants contribute to signalling and treatment resistance. Erasca is developing ERAS-0015 as a potential treatment backbone for RAS-mutant cancers, including combinations with agents targeting complementary tumour survival pathways.

The combination with navlimetostat therefore represents an effort to extend ERAS-0015 development beyond monotherapy by addressing additional molecular dependencies in pancreatic cancer.

Early Clinical Findings Support Further Evaluation

Erasca is currently evaluating ERAS-0015 in AURORAS-1, an ongoing Phase 1 dose-escalation trial involving patients with RAS-mutant solid tumours.

According to the company, early dose-escalation findings showed a favourable safety and tolerability profile, predictable linear pharmacokinetics and confirmed and unconfirmed partial responses across multiple tumour types and RAS mutation subgroups. Confirmed partial responses were observed at doses as low as 8 mg once daily.

These preliminary findings provide the clinical foundation for exploring ERAS-0015 in combination regimens. However, the company has not disclosed clinical efficacy or safety results for the proposed ERAS-0015 and navlimetostat combination.

Expanding the Combination Development Strategy

Erasca CEO Jonathan Lim said the collaboration would allow the company to investigate the potential of combining ERAS-0015 with complementary mechanisms of action, reinforcing its strategy of developing the molecule as a treatment backbone across RAS-mutant cancers.

The Phase 1/2 programme will provide an opportunity to evaluate the combination in a patient population with overlapping RAS mutations and MTAP-associated vulnerabilities. Trial initiation timelines, enrolment targets, dosing schedules and primary endpoints have not yet been disclosed.

The collaboration adds another combination strategy to the development programme for ERAS-0015. Its clinical relevance will ultimately depend on whether dual RAS and PRMT5 inhibition produces meaningful antitumour activity with an acceptable safety profile in patients with MTAP-deleted pancreatic cancer.

 Reference

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat, ERASCA, 17 November 2026

About the Writer

Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.


Share on Social Media
Scroll to Top